CLINICAL UTILITY OF A NEUROBLASTOMA MONOCLONAL ANTIBODY

在这项研究中，最近开发的单克隆抗体，Mab 126， 与神经节苷脂抗原GD 2反应的神经母细胞瘤， 研究其在诊断和管理方面的潜在应用 神经母细胞瘤 初步研究结果表明，GD 2的表达 抗原似乎仅限于神经直肠胚层肿瘤和组织， GD 2的血清水平可以作为血清学和肿瘤标志物， 神经母细胞瘤的诊断和治疗监测。 我们计划进行 一项前瞻性的、长期的研究，收集了更多的患者资料， 儿科肿瘤学小组的30多个成员机构。 我们将 评估组织中Mab 126检测到的GD 2抗原的价值 神经母细胞瘤的诊断和神经母细胞瘤的临床分期。 我们 将测试神经母细胞瘤血清学诊断的有效性，并将 将诊断时的GD 2血清水平与 神经母细胞瘤患者的临床特征和最终结果，以确定 其预后价值。 GD 2的血清水平将与 评估循环GD 2作为肿瘤的有用性的临床过程 用于监测神经母细胞瘤患者。 我们将寻找 存在GD 2循环抗体及其抗原-抗体 复杂的神经母细胞瘤患者，并确定其临床 本案无关 我们还计划检查Mab 126和抗体的作用， 抗GD 2抗体对神经母细胞瘤生长的影响 细胞及其GD 2抗原的表达。 这些承诺将 探讨Mab 126在组织诊断和血清学诊断中的应用价值 诊断，临床分期和诊断，以及治疗 神经母细胞瘤的监测。 它还可以提供第一个模型系统， 明确定义的肿瘤相关抗原与 它的抗体可以被分解。 （二）

In this research, a recently developed monoclonal antibody, Mab 126, reactive with a ganglioside antigen, GD2, on neuroblastoma will be investigated for its potential application to the diagnosis and management of neuroblastoma. Preliminary findings showed that the expression of GD2 antigen appears to be restricted to neurectodermal tumors and tissues and that serum levels of GD2 may serve as a tumor marker for both serological diagnosis and therapeutic monitoring of neuroblastoma. We plan to conduct a prospective, long-term study of patient materials collected from more than 30 member institutions of the Pediatric Oncology Group. We will assess the value of GD2 antigen as detected by Mab 126 in the tissue diagnosis of neuroblastoma and in clinical staging of neuroblastoma. We will test the validity of a serological diagnosis of neuroblastoma and will correlate the serum levels of GD2 at the time of diagnosis with the clinical features and final outcome of neuroblastoma patients to determine their prognostic value. The serum levels of GD2 will be correlated with clinical course to assess the usefulness of circulating GD2 as a tumor marker in monitoring neuroblastoma patients. We will search for the presence of circulating antibody to GD2 and their antigen-antibody complexes in patients with neuroblastoma and determine their clinical relevance. We also plan to examine the effects of Mab 126 and antibody against GD2 found in patients' sera on the growth of culture neuroblastoma cells and their expression of GD2 antigen. These undertakings will delineate the value of Mab 126 in the tissue diagnosis and serological diagnosis, in clinical staging and prognostication, and in therapeutic monitoring of neuroblastoma. It may also provide the first model system in which the interaction between a well-defined tumor-associated antigen and its antibody can be dissected. (2)